www.biopharmadive.com Open in urlscan Pro
2606:4700:4400::ac40:91e0  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content
Supported by
 * post
 * share
 * post
 * email

   
 * Reading Now CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in
   autoimmune disease By: Benjamin Fidler
 * Reading Now CAR-T therapy use expands in multiple myeloma By: Ned Pagliarulo
 * Reading Now CAR-T clinical trials in non-oncologic indications: Operational
   insights By: Fortrea
 * Reading Now J&J sees mixed performance from new multiple myeloma drugs By:
   Ned Pagliarulo
 * Reading Now AstraZeneca’s $80B sales plan leans on cancer drug expansion By:
   Jonathan Gardner
 * Reading Now Cell and gene therapy manufacturing: the next generation of
   startups By: Gwendolyn Wu
 * Reading Now Cellares deal highlights startups’ foothold in cell therapy
   production By: Ned Pagliarulo
 * Reading Now Iovance marks milestone with approval of ‘TIL’ cell therapy By:
   Benjamin Fidler

Supported by

Trendline


CELL THERAPY


National Institutes of Allergy and Infectious Diseases. (2016). “Human natural
killer cell” [Micrograph]. Retrieved from Flickr.

NOTE FROM THE EDITOR

About seven years ago, a group of experts gathered at the Food and Drug
Administration’s headquarters in White Oak, Maryland, to discuss a cutting-edge
leukemia treatment that had delivered remarkable results in early clinical
testing.

The treatment, consisting of patient immune cells genetically engineered to
attack cancer, was the first of its kind to reach the FDA and quickly won the
agency’s approval one month after that expert panel unanimously recommended its
use.

Since then, five other so-called CAR-T cell therapies have joined that treatment
on the U.S. market for several types of leukemia, lymphoma and multiple myeloma.
Studies now support their use earlier in a patient’s disease, rather than after
all other treatment options have been exhausted.

While uptake has been limited in some instances, cell therapy’s impact in cancer
care is growing, and biotech companies have continued to invest in ways to
improve it, such as through “off-the-shelf” options or by using different types
of immune cells. Some are exploring CAR-T outside of cancer, too, such as in
autoimmune disease.

Cell therapy’s emergence has also accelerated development of the technologies
needed to support the complex process of extracting immune cells from the blood,
engineering them and reinfusing back into patients. Drugmakers starting out can
now tap experienced contract manufacturers to aid their clinical development and
manufacturing.

Read on for a look at the current market for CAR-T cell therapies and what
biotechs are working on next.

Ned Pagliarulo Lead Editor
 * Reading Now CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in
   autoimmune disease By: Benjamin Fidler
   
 * Reading Now CAR-T therapy use expands in multiple myeloma By: Ned Pagliarulo
   
 * Sponsored CAR-T clinical trials in non-oncologic indications: Operational
   insights Sponsored content by Fortrea
   
 * Reading Now J&J sees mixed performance from new multiple myeloma drugs By:
   Ned Pagliarulo
   
 * Reading Now AstraZeneca’s $80B sales plan leans on cancer drug expansion By:
   Jonathan Gardner
   
 * Reading Now Cell and gene therapy manufacturing: the next generation of
   startups By: Gwendolyn Wu
   
 * Reading Now Cellares deal highlights startups’ foothold in cell therapy
   production By: Ned Pagliarulo
   
 * Reading Now Iovance marks milestone with approval of ‘TIL’ cell therapy By:
   Benjamin Fidler
   




CAR-T FOR LUPUS: THE ‘TIP OF THE ICEBERG’ FOR CELL THERAPY IN AUTOIMMUNE DISEASE

Large and small drugmakers see the effort as the first step towards using
cell-based medicines to treat a variety of common, inflammatory conditions.

By: Benjamin Fidler • Published Jan. 30, 2024

The clue came, as they often do, from an unexpected source. A year and a half
ago, a small study of five people in Germany pointed to a new direction for the
high-profile field of cell therapy.

The study showed a cellular medicine could drive a tough-to-treat form of lupus
into remission. While early, the finding suggested a technique used to create
powerful cellular treatments for cancer might also work against autoimmune
conditions like lupus, too.

“It’s very early days, but it’s exciting for the field to see this possibility,”
said cell therapy pioneer and University of Pennsylvania immunologist Carl June,
in an interview at the time.

The biopharmaceutical industry took note. Since the paper was published, a
number of drugmakers have revealed plans to develop cell therapies for lupus,
and nearly a dozen are now in clinical testing.

Updated results from that German study, presented at a medical meeting in
December 2023, indicate they may be right to invest. Among 15 people who had
lupus or one of two other autoimmune diseases and hadn’t responded to prior
treatment, all were in remission after receiving cell therapy. Some responses
have lasted two years.

“It’s the tip of the iceberg, but it looks extraordinary,” said Andy Plump,
Takeda Pharmaceutical’s head of research, in a recent interview. “The hope is
that this can expand to not just other refractory autoimmune diseases, but to
more common diseases.”

Challenges remain. Current cell therapies for cancer are associated with side
effects that in rare cases can be fatal, a risk that’s easier to accept for
people with deadly tumors than those with chronic health conditions. They’re
also complex to produce and administer, and only available at major treatment
centers, limiting their potential for wider use. Some believe newer
“off-the-shelf” alternatives may be a better fit.

Answers could come within the next few years from clinical trials just getting
underway. At least a dozen studies run by startups, biotechnology companies and
large pharmaceutical giants are either recruiting participants or soon will be.
Here’s where the field stands:


HOW IS LUPUS TREATED NOW?

Lupus is a chronic autoimmune condition that occurs when the body attacks
itself. The disease leads to pain and inflammation in many parts of the body,
from the skin and joints to internal organs like the kidneys or lungs. About 1.5
million people in the U.S. and 5 million worldwide have a form of the disease,
according to the Lupus Foundation of America, a patient advocacy group. For
reasons that aren’t quite clear, many of those affected are women of
childbearing age. Researchers aren’t certain what triggers the disease in the
first place, either.

Lupus has several types, the most common of which is known as systemic lupus
erythematosus, or SLE. It affects multiple organs and can involve a
constellation of symptoms, making it tough to diagnose. Lupus’ characteristic
‘flares’ arrive unpredictably and can last days or weeks. While most people can
manage their disease and live a long life, the condition can result in kidney
failure or death from heart-related complications.

There is no cure. Available treatments can help manage symptoms and counteract
the immune response associated with the disease. They include repurposed
anti-inflammatory or immunosuppressive therapies, steroids or antimalarials.

More recently, three medicines specifically developed for lupus — GSK’s
Benlysta, Aurinia Pharmaceuticals’ Lupkynis and AstraZeneca’s Saphnelo — have
reached market. Roche’s cancer drug rituximab is sometimes used off-label as
well, despite disappointing clinical results.

All have limitations, however. Not everyone responds to treatment and patients
can continue to have flare-ups, requiring them to try different treatments.
Additionally, drugs that blunt the immune system, like steroids, can leave
patients vulnerable to infection.


HOW COULD CELL THERAPY BE USED?

Six so-called CAR-T cell therapies are approved in the U.S. to treat leukemia,
lymphoma and multiple myeloma. When they work, these therapies can lead to
long-lasting benefit.

They’re made by genetically modifying a patient’s immune cells to spot proteins
found on the surface of cancerous B cells. These cells, which normally make
protective antibodies, are also implicated in an array of autoimmune diseases.
In lupus, for example, B cells go haywire and make antibodies that damage
healthy tissue.

CAR-T therapies wipe out B cells, whether cancerous or not. That effect led
Georg Schett and colleagues at the Friedrich Alexander University,
Erlangen-Nurnberg, to test CAR-T therapy in people with lupus.

Schett’s team published a case report in The New England Journal of Medicine in
2021, following up one later with results in four more study volunteers, which
were presented in Nature. They found the drug depleted B cell counts and drove
participants’ disease into remissions that persisted without using other drugs.

Notably, treated individuals still responded to vaccines and their levels of
infectious disease antibodies “largely remained intact,” wrote analysts at the
investment bank William Blair, in a recent report. Side effects were mild.

When B cells did regenerate, disease symptoms didn’t return, which the authors
suggested could support the idea that CAR-T therapy “reboots” the immune system.

To drugmakers, the findings indicate cellular therapies, if engineered right,
could potentially cure some autoimmune diseases.

“There’s a huge potential for patients to really benefit,” said Samit Hirawat,
the chief medical officer of Bristol Myers Squibb, in a recent interview.

Yet it’s still unclear how long responses will last, or whether people may need
to be re-treated later. The results may not be replicated as CAR-T therapies are
studied in large groups of people with lupus, either.

CAR-T also involves a chemotherapy “conditioning” regimen to prepare patients
for therapy. And treatment can cause serious immune and neurological side
effects that, in an autoimmune disease setting, “will not be acceptable to
patients and physicians,” wrote William Blair analysts.

More seriously, the Food and Drug Administration recently issued safety warnings
for all six available CAR-T therapies, following a review of reports of patients
developing secondary malignancies after treatment.

Those risks will require developers to mitigate CAR-T’s known safety issues.
Companies working on adapting the therapies say their goal is to fine-tune the
approach for use in autoimmune diseases.

“I think the whole industry is asking: how can we work on the benefit-risk
profile and the conditioning process so that, ideally, you can [treat patients]
earlier and earlier and not wait until they have severe, refractory disease?”
said Victor Bulto, head of Novartis’ U.S. division.


WHICH COMPANIES ARE WORKING ON CELL THERAPIES?

About a dozen companies have launched trials testing cell therapies in lupus,
according to a federal database. At least another six have received Food and
Drug Administration clearance to begin initial studies and could soon follow,
while others still have disclosed plans for testing.

Two cell therapy leaders, Novartis and Bristol Myers Squibb, started Phase 1
trials last year. They’re each testing newer versions of the products they
brought to market for cancer, tweaking them to cut manufacturing times, boost
safety and raise potency.

Bristol Myers’ Hirawat noted how Schett’s research suggests developers can
deliver benefit in lupus with lower and, theoretically, safer doses than in
cancer. That’s partly because there are fewer B cells to target in lupus than
there are cancerous cells in lymphoma or leukemia.

“We don’t anticipate, or want to see, the same safety profile as you saw in
malignancies,” he said.

SELECT LUPUS CELL THERAPIES IN FEDERALLY LISTED CLINICAL TRIALS

Company Cell therapy Development phase Trial number Indication Kyverna
Therapeutics KYV-101 Phase 1 NCT05938725 Lupus nephritis Gracell Biotechnologies
GC012F Phase 1 NCT05858684 SLE Novartis YTB323 Phase 1/2 NCT05798117 SLE Bristol
Myers Squibb CC-97540 Phase 1 NCT05869955 SLE Cartesian Therapeutics
Descartes-08 Phase 2 NCT06038474 SLE Miltenyi Biomedicine MB-CART19.1 Phase 1/2
NCT06189157 SLE ImmPACT Bio IMP-514 Phase 1/2 NCT06153095 SLE and lupus
nephritis iCell Gene Therapeutics BCMA-CD19 cCAR-T Phase 1 NCT05474885 SLE
Cabaletta Bio CABA-201 Phase 1/2 NCT06121297 SLE and lupus nephritis JW
Therapeutics Relma-cel Phase 1 NCT05765006 SLE

SOURCE: clinicaltrials.gov, companies

Alongside Bristol Myers and Novartis is Kyverna Therapeutics, a well-funded
biotech startup that went public in February. Kyverna’s lead program was
licensed from the National Institutes of Health and, like that of its larger
rivals, targets the protein CD19.

Also in testing are Gracell Biotechnologies, which AstraZeneca acquired last
year, Cartesian Therapeutics and startups Cabaletta Bio and ImmPACT Bio. Behind
them are an array of cell therapy companies that have said they will go after
lupus and other autoimmune diseases, like Fate Therapeutics, CRISPR Therapeutics
and Autolus Therapeutics.

China-based biotechs and academic researchers are investing in lupus research,
too. A federal database shows nearly a dozen academic or industry-backed trials
underway, including studies run by JW Therapeutics, Shanghai GeneChem and
Chongqing Precision Biotech.

Some that haven’t publicly announced trial plans, like Takeda, are interested:
“Even though we’re very far behind, we still think that we have a path,” Plump
said.

One reason: Not everyone is pursuing the same approach. Some companies have cell
therapies that target BCMA, another protein on B cells, as well as CD19. Some
are looking at different targets. And others are changing out components to
boost potency, or are tweaking conditioning regimens.

Meanwhile, companies like Artiva Biotherapeutics, Fate, and Sana Biotechnology
are trying approaches that rely on the cells of healthy donors. These so-called
allogeneic treatments have struggled as cancer therapies. But some developers
claim they may have an edge over personalized, or “autologous,” treatments in
autoimmune conditions. Here, they say, the advantages of donor-derived therapies
like cheaper production costs or lower rates of side effects will be more
important.

“Autologous cell therapy for autoimmune [disease] is going to be pretty
challenging,” said Carlo Rizzuto, managing director at Versant Ventures, a
venture firm that invested in allogeneic cell therapy developer Century
Therapeutics. “I do think that allogeneic off-the-shelf approaches, especially
the stem cell-based approaches, will have an advantage.”

Cell therapies could also face competition from newer antibody drugs designed to
better deplete B cell counts. Roche and Johnson & Johnson, for instance, have
drugs in mid- or late-stage testing for lupus.

“We will have to see how science evolves across all these modalities and see
which one works best for which patients,” said Bulto, of Novartis.

SELECT CELL THERAPIES FOR LUPUS CLEARED FOR TESTING BY FDA*

Company Cell therapy Development phase Trial number Indication Nkarta NKX019 To
be confirmed Not yet listed Lupus nephritis Sana Biotechnology SC291 Phase 1 Not
yet listed Lupus nephritis Artiva Biotherapeutics AB-101 To be confirmed Not yet
listed SLE and lupus nephritis Century Therapeutics CNTY-101 Phase 1 Not yet
listed SLE Luminary Therapeutics LMY-920 Phase 1 Not yet listed SLE Fate
Therapeutics FT-819 Phase 1 Not yet listed SLE

*Describes instances when the FDA has cleared an Investigational New Drug
application, but no trial is listed in clinicaltrials.gov database. SOURCE:
companies


WHAT’S NEXT?

Several clinical trial readouts this year and next could build on Schett’s
study. The tests underway are enrolling patients with SLE or lupus nephritis,
when the condition affects the kidneys. Some developers are recruiting people
with other autoimmune conditions as well, which could provide more clues as to
how broadly cell therapy might be applied.

Kyverna presented early results from a lupus nephritis study last year and is
recruiting patients. A fuller readout could come in 2025, according to a federal
database. The company is planning to test its treatment in systemic sclerosis,
myasthenia gravis and multiple sclerosis, too.

Novartis shared preliminary findings last year in a study testing its therapy,
YTB323, in SLE. More data are expected in the second half of 2024. Bristol Myers
should provide an early look at its program’s potential this year, too, and
intends to expand into MS, myositis and other conditions.

Cabaletta has said it will share results from patients with lupus or myositis in
the first half of 2024. ImmPACT and Sana could also report initial data in 2024.

Others, such as Fate, Nkarta and CRISPR intend to start dosing patients in 2024.
Startups with different approaches, like Luminary Therapeutics, could follow
afterwards.

Some of these efforts will need to bear fruit for investment to continue at such
a torrid pace. CAR-T’s potential in lupus alone “can’t sustain this massive
energy” in the industry, Plump said. “There are pieces that we’re just starting
to work through, but it’s an area of a lot of excitement.”

Article top image credit: Nemes Laszlo via Getty Images
Sponsored by Fortrea
Your agile partner for complex and novel clinical trials

Fortrea is your partner in developing cell, gene and other advanced therapies.
Together, we’ll improve your potential for success and make a difference in
urgent unmet medical needs.

Explore our services



CAR-T THERAPY USE EXPANDS IN MULTIPLE MYELOMA

Bristol Myers’ Abecma is cleared for relapsed or refractory forms of the blood
cancer after two or more prior lines of treatment, while J&J’s Carvykti is
available for use after one previous line.

By: Ned Pagliarulo • Published April 5, 2024 • Updated April 8, 2024

The Food and Drug Administration has cleared two multiple myeloma cell therapies
for earlier use treating the blood cancer, granting expanded approvals to
Bristol Myers Squibb’s Abecma and to Johnson & Johnson’s Carvykti.

The OKs come three weeks after a panel of FDA advisers agreed the benefits of
earlier treatment outweighed the risks, including concerns raised by agency
reviewers over data indicating an elevated chance of death among treated study
participants early on in the companies’ main trials.

Abecma, which is co-marketed by 2seventy Bio, is now available for people who
previously received at least two drug regimens for their multiple myeloma, while
Carvykti can be used after just one prior line of therapy. J&J developed
Carvykti together with Legend Biotech.

Overall, trial results showed that both Abecma and Carvykti substantially
reduced the risk of disease progression or death, compared to standard regimens.
But the safety concerns raised by the FDA were enough to put Friday’s approvals
somewhat in question.

Seeking advice, the FDA in mid-March convened an expert committee to debate
earlier use of the therapies. Ultimately, they found the benefits of both to be
substantial enough to look past the early death risk raised by the FDA, voting
11-0 in favor of Carvytki and 8-3 in support of Abecma.

In responding to the FDA’s concerns, Bristol Myers had cited patient crossover
from the control arm to treatment as confounding survival data. The advisory
panel also noted complications with the “bridging” therapy used prior to CAR-T
treatment, which may be different in clinical practice than in a trial.

Treatment benefit “is significant and offers our patients a chance of
significant time off therapy with associated quality of life improvement,” said
Christopher Lieu, a panelist and associate medical professor at the University
of Colorado, at the March 15 meeting. “But it’s a closer margin than I think we
would like, and patients will need to have in-depth discussions about the risks
and benefits.”

Both therapies target a protein called BCMA that’s found on malignant B cells in
people with multiple myeloma. Their earlier approvals for later-line treatment
added another option to a growing arsenal of therapies that have helped improve
outcomes for patients with the blood cancer.

Still, people with multiple myeloma often relapse or their cancer becomes
resistant to one treatment, requiring a switch to different regimens.

Abecma was previously cleared for relapsed or refractory disease in adult
patients who have received four or more prior regimens, including ones that
involve three of the main classes of multiple myeloma drugs.

Now, Abecma can be used in after two lines of therapy, provided patients are
“triple class-exposed,” or have received treatment that includes those three
types of drugs.

Carvytki can be used even earlier, as soon as after a patient’s first relapse.
The label specifies treatment for people who have received at least one line of
therapy that includes a so-called proteasome inhibitor and an immunomodulatory
drug. Patients’ disease must be resistant to treatment with a drug called
Revlimid.

“This product label difference offers significant commercial advantage for
Carvykti as its eligibility for use in [second-line multiple myeloma] patients
should limit the use of other BCMA CARTs in the following lines of therapy,”
wrote Jefferies analyst Kelly Shi in an April 7 client note.

CAR-T therapies are personalized, built from the immune cells of each individual
patient. Manufacturing is complex and can be challenging to get right every
time. Bristol Myers said it has a manufacturing success rate of 94% providing
Abecma in the commercial setting, while J&J said it aims to double production
capacity this year.

In addition to granting Carvykti an expanded approval, the FDA also cleared more
favorably manufacturing specifications, according to Shi.

Article top image credit: Peddalanka Ramesh Babu via Getty Images
Sponsored


CAR-T CLINICAL TRIALS IN NON-ONCOLOGIC INDICATIONS: OPERATIONAL INSIGHTS


Sponsored content
By Fortrea
By: Julie Maher, Senior Director, Rare Diseases, Advanced Therapies and
Pediatrics Team (RAPT); Fortrea • Published June 1, 2024

The number of non-oncologic CAR T-cell therapy trials has rapidly increased
since the first chimeric antigen receptor (CAR) T-cell therapy, KYMRIAH®, was
approved by the U.S. FDA for the treatment of acute lymphoblastic leukemia.[i]
As of January 2024, Citeline’s Trialtrove® data listed 66 CAR cell therapy
non-oncology trials, with 55 in Phase I/II, predominantly focusing on autoimmune
and inflammation indications.

Treatment approaches vary, but CD19 is the primary target for non-oncologic CAR
therapies in Citeline’s Trialtrove® data. A February 2024 publication reported a
follow-up of patients with systemic lupus erythematosus (SLE), idiopathic
inflammatory myositis and systemic sclerosis treated with CD19 CAR T-cell
transfer, finding that the treatments were “feasible, safe, and efficacious”[ii]
urging further clinical research.

This article provides operational considerations for sponsors developing CAR
T-cell therapies in non-oncologic indications spanning site identification and
support, patient education and logistics.

OPERATIONAL CHALLENGES IN NON-ONCOLOGIC CAR-BASED TRIALS

While transitioning a therapeutic technology initially developed for oncologic
indications into autoimmune indications has been previously demonstrated, for
example, with monoclonal antibodies, CAR-T treatments are more complex in terms
of administration, adverse event management and long-term follow-up (LTFU). At a
high level, the most significant challenges include:

Finding the optimal site: Depending on the indication, an institution or site
may have experience with cell and gene therapies but its investigator for the
indication may not yet have specific experience with CAR T-cell therapies. In
addition, institutions may have limited capacity or underestimate a trial’s
complexity and the long-term commitment required. The ideal institution or site
should have cross-functional expertise, such as an indication-specific principal
investigator (PI), a team experienced with CAR-based cell therapies, adequate
support staff and hematology/oncology specialists that understand safety
profiles and can also manage lymphodepletion, chemotherapy/immunotherapy any
associated toxicities following treatment administration.  

Promoting patient access and education: Sites need access to indication-specific
and age-specific populations, and ideally the ability to accept referred and
international patients if studying a rare disease. From the perspective of
educating families and enabling patient advocacy support in these trials,
understanding the patient journey and their acceptance of the trial protocol is
crucial for recruitment and retention efforts, especially as the risk/benefit
profile may vary from treating life-threatening cancer.

Handling complex logistics: CAR-T trials often experience a slow start or
limited progress as they respond to manufacturing limitations as well as
frequent protocol amendments. Logistics supply chain challenges can also arise,
depending on the location of the pharmacy within the institution as well as the
location of a manufacturing or distribution site.

INCREASING OPERATIONAL EFFICIENCIES

Reflecting on lessons learned in oncology CAR-T cell studies, the following
tactics can help drug development sponsors and their partner CROs advance more
efficient and effective studies in non-oncologic CAR T-cell therapy trials.

Forming a multidisciplinary collaboration: In partnership with the sponsor and
the CRO, sites could form a “Cell Therapy Board” to actively bridge the gap
between current CAR-T cell therapy experts and any “newcomers.”This
collaboration helps build a strong rapport early in the process, initiates
critical protocol feedback, promotes continuous engagement and strengthens focus
on the patients.

Starting slow to finish fast: Investing time upfront in planning and mapping out
processes and procedures helps identify potential roadblocks, like regulatory
and institutional policies, contractual issues across hospital departments and
operational logistics of the cell therapy product. Anticipating these
bottlenecks allows sponsors and CROs to provide timely solutions and support new
challenges over time.

Building a network of sites: Not all enlisted sites may initially have specific
cell and gene therapy experience. Employing a “hub and spoke model” allows a
highly specialized center to handle most complex tasks and procedures, such as
selecting suitable patients, treatment planning and execution and overseeing the
prevention and management of treatment-related toxic effects. The more standard
and less complex study procedures can be administered at secondary sites, closer
to the patient population, promoting a patient-centric approach.

As clinical research of CAR-T cell therapies expands beyond oncology, sponsors
and CROs should leverage insights from oncology trials to inform the setup of
non-oncology trials.

To learn more about how Fortrea can help advance CAR T-cell studies in
non-oncology indications, visit us online.

--------------------------------------------------------------------------------

References

[i] U.S. FDA. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for
cytokine release syndrome. Sept. 2017.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome
Accessed 24 Apr. 2024

[ii] Müller, F, Taubmann, J, Bucci, L, et al. CD19 CAR T-Cell Therapy in
Autoimmune Disease — A Case Series with Follow-up. N Engl J Med. 2024 Feb
22;390(8):687-700. doi: 10.1056/NEJMoa2308917.

Article top image credit: Nemes Laszlo via Getty Images
Sponsored by Fortrea
Your agile partner for complex and novel clinical trials

Fortrea is your partner in developing cell, gene and other advanced therapies.
Together, we’ll improve your potential for success and make a difference in
urgent unmet medical needs.

Explore our services



J&J SEES MIXED PERFORMANCE FROM NEW MULTIPLE MYELOMA DRUGS

Sales of Tecvayli, broken out by J&J for the first time, surpassed Wall Street’s
forecasts, while the “timing of orders” for Carvykti held back growth for the
cell therapy.

By: Ned Pagliarulo • Published April 16, 2024

Sales of Johnson & Johnson’s multiple myeloma medicine Tecvayli more than
doubled in the first quarter versus the same period last year, boosting the
pharmaceutical company’s oncology business while its cell therapy for the blood
cancer, Carvykti, underperformed.

The first quarter figures released April 16 by J&J were the first time it has
broken out sales of Tecvayli, which was approved in the U.S. in late 2022. The
dual-targeting antibody drug brought in $133 million between January and March,
above analysts’ estimates.

Tecvayli’s growth contrasted with Carvykti, sales of which were flat in the
first quarter compared to the final three months of last year. J&J, which has
been working to improve how it produces the complex cell treatment, cited the
timing of orders as the main reason for Carvykti’s slower-than-expected sales.

J&J has put multiple myeloma drug development at the center of its pharma
business strategy, setting a target of $25 billion in sales by 2030 and at least
50% share of patient treatment.

For much of the past decade, its oncology business has been led by Darzalex, an
antibody that’s become a backbone therapy for multiple myeloma. Sales have
continued to grow, rising 19% year over year in the first quarter to about $2.7
billion.

Tecvayli and Carvykti, along with a newer medicine called Talvey, are meant to
build on Darzalex by offering new ways to target the blood cancer, as well as
opportunities for treatment combinations. Tecvayli and Talvey are both
bispecific antibodies that bind to different myeloma cell proteins, while
Carvykti is a personalized cell therapy.

Manufacturing the latter is a complicated undertaking and for months, J&J has
been working to improve how reliably it can make Carvykti. The company claimed
it’s doubled capacity since last year, adding new production facilities and
bringing on contract suppliers.

The increased supply will be needed if demand grows as J&J expects following the
Food and Drug Administration’s recent decision to approve earlier Carvykti
treatment. The therapy can now be used after only one prior drug regimen for
people with relapsed or refractory multiple myeloma, compared to the previous
indication for use after four lines of therapy.

While Carvykti sales were flat in the first quarter, Jennifer Taubert, J&J’s
head of innovative medicine, cited the “timing of orders and when they were
actually delivered and billed.”

“Nothing [...] to really see there,” she added, on a Tuesday call with analysts.
“We do anticipate continued growth for this asset, particularly in the second
half versus the first half.”

J&J faces competition from Bristol Myers Squibb, which has a rival cell therapy
called Abecma, as well as from other companies like Pfizer that have developed
bispecific antibodies.

Taubert noted Tecvayli has seen strong adoption in the U.S., as well as in
countries like Germany and France, and said it was performing well versus the
competition.

Overall, J&J’s cancer drug sales totaled $4.8 billion in the first quarter, up
17% year over year and accounting for some 35% of the company’s pharma business.

Article top image credit: Mario Tama via Getty Images


ASTRAZENECA’S $80B SALES PLAN LEANS ON CANCER DRUG EXPANSION

The U.K. drugmaker aims to catch up in developing new tumor-fighting
technologies — areas where it has lagged behind leaders like Novartis and J&J.

By: Jonathan Gardner • Published May 21, 2024

AstraZeneca’s plan to reach $80 billion in sales by 2030 relies heavily on a
slate of roughly one dozen cancer drugs it expects will become blockbuster
sellers at their peak, according to a presentation to investors that executives
outlined in late May.

One of the drugs, the lung cancer treatment Tagrisso, has already exceeded $5
billion in annual sales and another, Imfinzi, is approaching that mark. But four
use technologies AstraZeneca hasn’t previously employed and will either take on
or trail products from rival drugmakers.

Broadly, AstraZeneca aims to develop drugs that supplant toxic chemotherapies as
well as immunotherapies known as checkpoint inhibitors. Its large pipeline of
antibody-drug conjugates, which add tumor cell-targeting to chemical toxins,
will play a large role in achieving the former goal.

AstraZeneca has reinvented itself over the past decade, shifting from its prior
focus on mental health, respiratory and cholesterol drugs to emphasize oncology.
There, its strength has been in targeted therapies and in antibody-drug
conjugates, as it has come late to fields like immunotherapy and
radiopharmaceuticals. Imfinzi, the company’s flagship immunotherapy, arrived
fifth to market in the U.S. and last year earned sales that were one-fifth of
Merck & Co.’s Keytruda, the leader in the space.

AstraZeneca plans to change that picture. In immunotherapy, it’s developing
bispecific antibodies that target the PD-1 pathway. One, called rilvegostomig,
binds to another immunity-modulating pathway called TIGIT, which has proven a
difficult target even in combination with PD-1 drugs.

Another, known as volrustomig, binds to PD-1 and a target called CTLA-4,
essentially duplicating a two-drug combination of Imfinzi with another
immunotherapy called Imjudo.

AstraZeneca also plans to make a mark in cell therapy, which has so far been led
by Novartis, Gilead and Bristol Myers Squibb, as well as biotechnology companies
like Legend Biotech and Bluebird bio. Leading AstraZeneca’s efforts is a
dual-acting therapy that hits a protein active on multiple myeloma cells, along
with CD19. The company claims it can make that drug, which would compete with
Legend and J&J’s Carvykti and Bristol Myers’ Abecma, in a few days, rather than
the weeks current CAR-T therapies take to produce.

Outside of immunotherapy, AstraZeneca is advancing a new type of hormone therapy
for breast cancer that it’s testing in post-surgical and inoperable settings,
paired with types of targeted therapies in some cases. In breast cancer, it is
also studying a so-called PARP inhibitor known as saruparib, which could
potentially replace its $2 billion-a-year drug Lynparza.

Antibody-drug conjugates, which pair the tumor-targeting of antibodies with the
cell-killing power of chemotherapies, will continue to play a large role in
AstraZeneca’s cancer drug plans, too.

The company already markets one, the breast cancer drug Enhertu, and has another
now before regulators, called datopotamab deruxtecan and also for breast cancer.
Peter Welford, an analyst at Jefferies, forecasts that latter drug will earn
nearly $6 billion in sales in 2030.

AstraZeneca has six other clinical-stage ADCs. Combined, its ADC assets could be
used in 17 different types of cancer.

Beyond 2030, the drugmaker expects to add radiopharmaceuticals, or hybrid
radiation-emitting drugs, to its arsenal. AstraZeneca paid $2.4 billion in March
to acquire Fusion Pharmaceuticals, a developer of such products that has a
prostate cancer drug in Phase 2.

Article top image credit: Christopher Furlong via Getty Images
Sponsored by Fortrea
Your agile partner for complex and novel clinical trials

Fortrea is your partner in developing cell, gene and other advanced therapies.
Together, we’ll improve your potential for success and make a difference in
urgent unmet medical needs.

Explore our services



CELL AND GENE THERAPY MANUFACTURING: THE NEXT GENERATION OF STARTUPS

At least six companies have emerged to help unstick what developers say is a
“bottleneck” in advancing complex genetic treatments.

By: Gwendolyn Wu • Published June 20, 2023

Developing a new drug is a long, expensive process that comes with a high risk
of failure, often because would-be medicines are unsafe or ineffective.

For companies specializing in cell or gene therapies, an equally pressing
concern is figuring out how to reliably make their products. Unlike small
molecule or antibody drugs, genetic medicines typically involve a variety of
specialized parts woven together through a complex process.

“Ex vivo,” or outside-the-body, treatments can involve a multi-week process for
collecting, multiplying and modifying a patient’s cells in a laboratory. Even
the simpler “in vivo” therapies have multiple pieces, including engineered
viruses and synthetic genetic material, that are challenging to produce at
scale.

The approvals of a dozen cell- and gene-based medicines for cancer and inherited
diseases in recent years has given young drugmakers a path to pursue. But most
of those approvals were won by large pharmaceutical or biotechnology companies
that invested heavily in manufacturing. Startups, by contrast, don’t yet have
that luxury.

Still, cell and gene therapy research is booming. More than 2,200 clinical
trials testing these types of treatments were ongoing globally as of 2022,
according to the Alliance for Regenerative Medicine. The surge has often
outstripped the capacity of large contract manufacturers, leaving startups
facing waitlists that can stretch one to two years.

A growing group of new manufacturers aim to help. Since 2017, at least half a
dozen companies have launched with plans to ease the “bottlenecks” slowing down
aspiring cell and gene therapy developers. Many have been started by veterans of
the young field and gotten the backing of top venture firms. Here’s what they
aim to accomplish and how their work is progressing:


WHAT ARE THE MAIN BOTTLENECKS IN CELL AND GENE THERAPY MANUFACTURING?

Cell and gene therapies involve materials that aren’t used in many of the other
products the pharma industry is well-versed in producing.

Scientists design synthetic genetic material to deliver into patients, either
via their own cells, benign viruses known as vectors or specially made bubbles
of fat. Constructing these treatments is tricky even in a research setting,
where small amounts of such material might be required for early experiments.
But it’s much harder for companies running clinical trials, or preparing for
mass production.

Manufacturing delays can wreak havoc on young companies, causing them to miss
milestones that could endanger future funding. Established gene therapy biotechs
like UniQure or BioMarin Pharmaceuticals have spent years and millions of
dollars to build their own plants. But startups and academic labs — where a
number of the approved cell and gene therapies originated — can’t afford that.

“Academics have truly cutting-edge research, and I have been blown away by some
of the creative ideas, novel modalities and breakthrough innovations that came
about,” said Ran Zheng, the CEO of Landmark Bio, a Massachusetts-based company
that caters to cell and gene therapy developers. “But that information needs to
be translated into therapeutics, and this is the biggest, and probably the
first, hurdle [startups] have to overcome.”

Turning to contract manufacturers like Thermo Fisher and Catalent can be a
solution, but brings problems of its own. Transferring technology from a small
lab to a larger organization can be arduous and require troubleshooting for
glitches that arise in the process.

Big CDMOs may also prioritize more lucrative work with larger biotech and
pharmaceutical firms. And they’re struggling to meet the surging demand for cell
and gene therapy manufacturing tools themselves.

Building up capabilities internally can be costly for startups. Viral vectors,
for instance, are expensive to make and handle.

“You often see companies trying to own their own manufacturing and
unfortunately, in this environment, if the product’s not successful, that’s a
heavy capital and operating expense to carry,” said Mike Paglia, a senior
executive with ElevateBio, a richly funded startup that helps manufacture cell
and gene therapies.


HOW ARE THESE STARTUPS TRYING TO CHANGE THAT?

Rather than compete directly with larger CDMOs, some manufacturing startups aim
to provide a more cost-efficient path for companies to develop in-house
production capabilities. To appeal to younger biotechs that may need them, they
are building relationships earlier and providing more services to attract
first-time founders and small teams.

Many of these conversations take place long before an application to begin human
testing, so these smaller manufacturers work to teach startups about raw
material control strategies and set realistic timelines to gather early clinical
data.

“Traditional CDMOs are like a kitchen, you’ll give them a recipe and they make
an entree,” said Zheng, who previously worked in manufacturing and operations at
Orchard Therapeutics and Amgen. “That’s all they do. We’re not like a kitchen
where you just simply state the recipe. We actually ask our clients what ideas
they have and we develop the recipe with them.”

Some clients start from near the beginning, working with these newer
manufacturers from the moment they identify a lead candidate.

ElevateBio and Landmark Bio both help startups with laboratory studies to ensure
that, down the line, they’re familiar with how to transfer their drugmaking
technology to the companies that might eventually produce their therapies.

Paglia, who previously worked at Bluebird bio, said the biggest hurdle for him
and his former colleagues was transferring their technology to contract
manufacturers.

“Whether it was manufacturing our lentiviral vectors or cell therapy products,
it took tremendous amounts of oversight to get those processes right because of
the infancy of the industry,” he said.

Still, outsourcing to a dedicated manufacturer can save biotechs millions of
dollars in the long term, Paglia said, allowing them to put that money toward
additional clinical studies. That has meant steady demand for CDMOs, and created
business for new startups trying to help.

Manufacturing startups have also attracted academics and nonprofits that
struggled to get time with larger CDMOs. Landmark has worked with researchers
who have received National Institutes of Health grants, for example.

Ultimately, improving manufacturing might give companies an opportunity to
rethink how they price cell and gene therapies, which are some of the costliest
medicines to make. The few companies that have reached market have noted these
high costs in setting price tags that range from hundreds of thousands to
millions of dollars.


WHO ARE THE STARTUPS IN THE SPACE?

At least six biotech startups have launched since 2017 to address shortfalls in
cell and gene therapy manufacturing.

The most richly funded, ElevateBio, has raised about $1.3 billion since it began
working with drugmakers. It’s also spun out its own biotech startup with Boston
Children’s Hospital to develop more convenient alternatives to current cancer
cell therapies.

More recently, Ascend Cell & Gene Therapies in the U.K. emerged from stealth
armed with $130 million in funding and led by industry veterans. It’s focused on
adeno-associated viruses, a heavily used type of viral vector, and has acquired
some of its capacity and technology from the struggling Freeline Therapeutics.

“AAV manufacturing is complex and needs teams that show real expertise and
ownership,” said one of Ascend’s founding investors, Tim Funnell of Monograph
Capital, in a statement on the company’s launch. “This led many advanced
modality biotech developers to build their own internal CMC capabilities.
However, these companies are now finding it difficult to sustain and fully
utilize their facilities.”

There are smaller ventures, too. A pair of University of Pennsylvania
researchers who worked on the cell therapy Kymriah and the gene therapies
Zolgensma and Luxturna launched VintaBio last April. Months before in January
2023, biotech startup creator Versant Ventures debuted Vector BioMed to help
supply startups with the “lentiviral” vectors often used in ex vivo treatments.

SELECT LIST OF STARTUPS SPECIALIZING IN CELL, GENE THERAPY MANUFACTURING

Company Notable investors Funding ElevateBio AyurMaya Capital, Matrix Capital,
Softbank Approx. $1.3B Shape Therapeutics NEA, Decheng Capital, Breton Capital
$147.5M Ascend Cell & Gene Therapies Monograph, Abingworth, Petrichor $132.5M
Landmark Bio Harvard University, MIT, Fujifilm, Alexandria Real Estate, Cytiva
$75M VintaBio Decheng Capital $65M Vector BioMed Viking Global Investors, Casdin
Capital $15M

SOURCE: Companies


WHAT’S THE STATUS OF THEIR WORK?

With demand for more CDMOs at an all-time high, these startups are partnering
with drugmakers straight out of the gate. Though many rely on capital infusions
from venture firms, they also can generate cash from their work early on,
bringing returns to investors well before a typical biotech might.

Landmark Bio had its first customer “even before we put a sign on the door,”
Zheng said in October. In early June, it announced a partnership with InnDura, a
new biotech company focused on “natural killer” cell research.

ElevateBio, having been around for some years, boasts a larger client list,
noting in a May fundraising announcement that it added more than 15 new
biopharmaceutical partners over the past year. Its subsidiary Life Edit
Therapeutics is collaborating with large drugmakers like Novo Nordisk and
Moderna.

VintaBio has a 22,500-square-foot facility in Philadelphia that’s now open for
business, while Vector BioMed is working out of Gaithersburg, Maryland.

Shape Therapeutics is somewhat different, as it’s working on its own research,
too. But it has also hinted at playing a manufacturing role, developing a new
kind of cell line for producing adeno-associated viruses and indicating plans to
build a factory where other companies can make their therapies.

Article top image credit: Permission granted by Landmark Bio


CELLARES DEAL HIGHLIGHTS STARTUPS’ FOOTHOLD IN CELL THERAPY PRODUCTION

Bristol Myers Squibb is partnering with Cellares in a bid to both scale and
speed manufacturing of CAR-T treatments for cancer.

By: Ned Pagliarulo • Published April 22, 2024

Bristol Myers Squibb is turning to a manufacturing startup to help produce
cancer cell therapies faster, announcing April 22 a partnership with the South
San Francisco, California-based Cellares.

The deal, which reserves Cellares’ production capacity for Bristol Myers’ use,
is worth up to $380 million in upfront and milestone payments. Cellares will
handle technology transfer of certain Bristol Myers cell therapies to its
automated manufacturing platform, dubbed the Cell Shuttle.

Bristol Myers currently sells two so-called CAR-T cell therapies, Breyanzi for
lymphoma and Abecma for multiple myeloma, and has several others in development.
In a statement, Lynelle Hoch, head of the pharmaceutical company’s cell therapy
unit, said the Cellares deal would help it meet demand for CAR-T therapies “now
and in the future.”

Made from patients’ own immune cells, CAR-T therapies are personalized
treatments. Their production is precisely choreographed, as frozen cells are
brought to manufacturing hubs where they are engineered and expanded into a
cancer-seeking drug product. It’s laborious, time-consuming and costly.

Currently, CAR-T manufacturers need somewhere between two to three weeks to turn
around a therapy for use in treating a patient. Companies like Cellares aim to
improve on that standard through a variety of methods, among them automating
production and moving manufacturing closer to treatment sites.

Cellares’ chief solution is along the lines of the former. The startup, which
has raised more than $350 million from a group of investors that includes
Bristol Myers, pitches its Cell Shuttle platform as both cheaper and more
efficient than existing processes.


Cellares co-founders Omar Kurdi (left) and Fabian Gerlinghaus stand next to
their company’s first “Cell Shuttle” manufacturing pod.
Permission granted by Cellares
 

Resembling a sort of giant MRI machine, the Cell Shuttle is a miniature factory,
housing all the technologies needed to make a CAR-T drug dose. Cellares claims
it can reduce manufacturing failure rates, require drastically less labor and
shave 50% off of average production costs.

The startup will dedicate multiple Cell Shuttles and associated quality control
systems for Bristol Myers under the partnership. The shuttles will be housed in
facilities located in the U.S., Europe and Japan, the companies said. Cellares’
current commercial-scale facility is in New Jersey.

In an email, a spokesperson for Cellares also noted the deal “strengthens
Cellares’ position as a U.S. manufacturer” at a time when Congress is
considering legislation that could restrict U.S. drugmakers from working with
Chinese biotechnology companies like WuXi Apptec.

“This agreement with Bristol Myers Squibb is aligned with our strategy of
establishing a global network of high-throughput, automated Smart Factories to
meet the growing and worldwide demand for cell therapies,” said Fabian
Gerlinghaus, Cellares’ CEO and co-founder, in a statement.

Article top image credit: Meletios Verras via Getty Images
Sponsored by Fortrea
Your agile partner for complex and novel clinical trials

Fortrea is your partner in developing cell, gene and other advanced therapies.
Together, we’ll improve your potential for success and make a difference in
urgent unmet medical needs.

Explore our services



IOVANCE MARKS MILESTONE WITH APPROVAL OF ‘TIL’ CELL THERAPY

The company’s therapy, which will be sold as Amtagvi, is the first cellular
medicine built from tumor-infiltrating lymphocytes to reach market.

By: Benjamin Fidler • Published Feb. 20, 2024

The Food and Drug Administration has cleared a new kind of cell therapy,
granting Feb. 20 an accelerated approval to Iovance Biotherapeutics’ Amtagvi for
people with an advanced form of skin cancer.

Amtagvi is the first marketed cellular medicine made by engineering immune cells
known as tumor-infiltrating lymphocytes, or TILs. It’s for people whose melanoma
can’t be surgically removed or has spread to other parts of the body, and is
meant to be used after other medicines.

The FDA’s OK was based on data showing Amtagvi shrank tumors in testing, a
benefit that must be confirmed in an ongoing Phase 3 trial. Iovance set the
drug’s list price at about $515,000, the highest of any cell-based medicine for
cancer in the U.S. Its prescribing information includes warnings for the risk of
low blood cell counts, severe infections or kidney problems.

Amtagvi’s approval has been a long time coming for Iovance.

TIL therapy originated from research at the National Institutes of Health in the
1980s. It took decades to fine-tune, and Iovance had to overcome multiple
regulatory delays bringing the therapy, formerly known as lifileucel, to market.

Its clearance is the “culmination of scientific and clinical research efforts,”
said Peter Marks, director of the FDA’s Center for Biologics Evaluation and
Research, in a statement.

An estimated 8,000 people die from melanoma each year, according to Iovance.
Until now, there haven’t been drugs available for people whose cancers progress
after a commonly used immunotherapy or targeted cancer medication.

Iovance must now prove it can manufacture and deliver a cell therapy, a
complicated task that has challenged even large drugmakers like Gilead Sciences,
Novartis and Bristol Myers Squibb, which sell a different kind of cell therapy
for a range of blood cancers.

Amtagvi is derived from a tumor sample that’s surgically removed. Select immune
cells that have “infiltrated” the tumor are isolated, grown and filtered via a
weekslong manufacturing process. It currently takes Iovance 34 days from the
time a sample is received to make and ship back each personalized TIL therapy —
longer than with the CAR-T cell therapies from Gilead, Novartis and Bristol
Myers.

“We think we can improve on it over time,” said CEO Frederick Vogt, on a
conference call with analysts.

Executives said 30 treatment centers will be active initially, climbing to over
50 within 90 days of the FDA’s original approval decision date of Feb. 24.

Still, Stifel analyst Benjamin Burnett noted there’s some questions among
experts as to how many of those centers are currently capable of administering
Amtagvi. There’s also debate among investors about demand and the complex
logistics involved.

“Cell therapy launches have been clunky,” Burnett wrote in a research note.

For its part, the company anticipates “strong market access and patient
reimbursement” given early response from payers, Jim Ziegler, the company’s
executive vice president of commercial, said. The majority of patients are on
commercial insurance, he said.

“We expect a bolus of patients coming through as the product launches and we
start to see the manufacturing flow,” said Vogt.

Iovance wouldn’t detail how much revenue it expects to earn. But the company’s
current manufacturing capacity and pricing imply Amtagvi could generate $185
million in its first three quarters on the market, wrote Jefferies analyst
Michael Yee.

“Consensus numbers look doable,” Yee wrote in a client note, adding that Iovance
“would make a nice tuck-in for big pharma, who could leverage this even better.”

Article top image credit: Courtesy of Iovance Biotherapeutics

Your agile partner for complex and novel clinical trials

Fortrea is your partner in developing cell, gene and other advanced therapies.
Together, we’ll improve your potential for success and make a difference in
urgent unmet medical needs.

Explore our services



INSIDE THE WORLD OF CELL THERAPIES

While uptake has been limited, cell therapy’s impact in cancer care is growing,
and biotech companies have continued to invest in ways to improve it, such as
through “off-the-shelf” options or by using different types of immune cells.
Explore the current market for cancer cell therapies and what biotechs are
working on next.

INCLUDED IN THIS TRENDLINE

 * AstraZeneca’s $80B sales plan leans on cancer drug expansion
 * Cellares deal highlights startups’ foothold in cell therapy production
 * J&J sees mixed performance from new multiple myeloma drugs

Our Trendlines go deep on the biggest trends. These special reports, produced by
our team of award-winning journalists, help business leaders understand how
their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.